26
20
Brain Tumor Reports

Volume 12 Number 2
February 2012

Home > Publications > Brain Tumor Reports > Volume 12, Year 2012 > Number 2, February°


CONTENTS



BRAIN TUMORS
GLIOBLASTOMA
GLIOMAS
MEDULLOBLASTOMA





BRAIN TUMORS



Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, Aerts I, Bérard PM, Bourdeaut F, Leblond P; on the behalf of the Comité Pharmacologie of the SFCE.
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends.
Pediatr Blood Cancer. 2012 Jan 27. doi: 10.1002/pbc.24066. [Epub ahead of print]




Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A; RARECARE working group.
Epidemiology of glial and non-glial brain tumours in Europe.
Eur J Cancer. 2012 Jan 6. [Epub ahead of print]





GLIOBLASTOMA



Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Häcker S, Vellanki SH, Lausen J, Debatin KM, Fulda S.
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Oncogene. 2012 Jan 23. doi: 10.1038/onc.2011.614. [Epub ahead of print]




Bleeker FE, Molenaar RJ, Leenstra S.
Recent advances in the molecular understanding of glioblastoma.
J Neurooncol. 2012 Jan 20. [Epub ahead of print]




Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, Dexter M, Cook R.
Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000-2008): Findings of a multicenter Australian study.
Surg Neurol Int. 2011;2:176. Epub 2011 Dec 13.




Haar CP, Hebbar P, Wallace GC 4th, Das A, Vandergrift WA 3rd, Smith JA, Giglio P, Patel SJ, Ray SK, Banik NL.
Drug Resistance in Glioblastoma: A Mini Review.
Neurochem Res. 2012 Jan 10. [Epub ahead of print]




Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P.
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Acta Neuropathol. 2012 Jan 15. [Epub ahead of print]




Iliadis G, Kotoula V, Chatzisotiriou A, Televantou D, Eleftheraki AG, Lambaki S, Misailidou D, Selviaridis P, Fountzilas G.
Volumetric and MGMT parameters in glioblastoma patients: Survival analysis.
BMC Cancer. 2012 Jan 3;12:3.




Montano N, Cenci T, Martini M, D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, De Maria R, Larocca LM, Pallini R.
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited.
Neoplasia. 2011 Dec;13(12):1113-21.




GLIOSARCOMA


Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH.
Clinicopathologic and genomic features of gliosarcomas.
J Neurooncol. 2012 Jan 20. [Epub ahead of print]





GLIOMAS



Arbizu J, Tejada S, Marti-Climent JM, Diez-Valle R, Prieto E, Quincoces G, Vigil C, Idoate MA, Zubieta JL, Peñuelas I, Richter JA.
Quantitative volumetric analysis of gliomas with sequential MRI and (11)C-methionine PET assessment: patterns of integration in therapy planning.
Eur J Nucl Med Mol Imaging. 2012 Jan 19. [Epub ahead of print]





MEDULLOBLASTOMA



Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO.
Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations.
Cell. 2012 Jan 20;148(1-2):59-71.